

Who We Serve

Our patient-first collaborative approach accelerates drug development and brings life-changing therapies to patients faster – driven by our mission to end NF.

What Is NF?

NF is a group of genetic conditions that cause tumors to grow on nerves throughout the body. NF includes neurofibromatosis type 1 (NF1) and all types of schwannomatosis (SWN), including NF2-related schwannomatosis (NF2-SWN). NF impacts everyone differently and may lead to blindness, deafness, bone abnormalities, disfigurement, learning challenges, disabling pain, or cancer.

But thanks to donors and partners like you, **patients and families living with NF will see a better tomorrow.**

BECAUSE OF PROGRESS
POWERED BY YOU,
PATIENTS WITH NF **WILL**
SEE A BETTER TOMORROW

Together, we can improve lives and bring hope to millions of patients living with NF.

To donate or learn more, visit
ctfeurope.org.



Children's Tumor Foundation Europe
+32460205252 | connect@ctfeurope.org
ctfeurope.org

ABOUT THE CHILDREN'S TUMOR FOUNDATION EUROPE

The Children's Tumor Foundation Europe is the patient-centric drug discovery engine for NF. Trusted by patients and providers, we drive treatments, advance care, and deliver faster results for over 4 million patients affected by neurofibromatosis or schwannomatosis.

Everything we do is to
drive treatments for
NF patients.



Your Support Changes Lives

Launched in 2018, CTF Europe is building a strong foundation for NF research and patient support in Europe. As a partner organization to CTF in the United States, CTF Europe is leading the fight to end NF by driving groundbreaking research, expanding knowledge, and improving care for patients and families. Every donation makes a difference, and here's why:

- **Driving Innovation:** From early discovery to clinical trials to approved treatments, your support helps turn research into real-life solutions.
- **Collaborative Approach:** By uniting patients, families, researchers, and industry leaders, we're accelerating the pace of progress.
- **Immediate Impact:** Donations support critical resources for families today, while funding the breakthroughs of tomorrow.



We Have A Global Track Record

Research Supported

- **\$200M Invested in NF Research Worldwide:** Your donations are driving impactful advancements in NF research.
- **Strategic Investments:** We fund projects that push the boundaries of NF treatment.

Approved and Emerging Treatments

- **Koselugo:** The first EMA and FDA-approved treatment for NF1, changing lives globally.
- **Mirdametinib:** A promising second treatment for NF1, awaiting EMA and FDA approval.

Clinical Trials and Breakthroughs

- **60+ Active NF Clinical Trials in the U.S.:** Pioneering research is underway.
- **Brigatinib for NF2-SWN:** A major breakthrough in treatment for NF2-SWN.
- **Innovative NF1 Platform Trial Design:** Submitted to EMA, expediting results for patients.

Patient and Clinic Networks

- **Global NF Patient Registry:** Connecting patients and healthcare providers worldwide.
- **European and U.S. NF Clinic Networks:** Ensuring comprehensive care for NF patients.



How You Can Help

**Only Six Clinical Trials for NF Are Active in Europe
We Can Change That—Act Now!**

- **Donate:** Scan the QR code or visit ctfeurope.org/donate. Your contribution powers groundbreaking research and treatments.



- **Network:** Build a coalition of support to amplify our impact.
- **Raise Awareness:** Share information about NF and CTF Europe—your voice makes a difference.

